FDA’s Approach To Combination Pediatric Therapies: Monotherapy Comes First
This article was originally published in The Pink Sheet Daily
Executive Summary
Limited data limits the ability of companies to move to combination strategies, members of an advisory panel cautioned during a review of two checkpoint inhibitors.
You may also be interested in...
Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.